Document Detail

Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
MedLine Citation:
PMID:  15963699     Owner:  NLM     Status:  MEDLINE    
The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18-year-old young man presenting HPPD after a mixed intoxication with psylocibin and cannabis. This report shows symptomatic recurrences persisting more than 8 months. Various differential diagnoses were evoked and our therapeutic strategies were described.
Marie-Laure Espiard; Laurent Lecardeur; Pascale Abadie; Isabelle Halbecq; Sonia Dollfus
Related Documents :
17261449 - Esophageal involvement as an initial manifestation of churg-strauss syndrome.
1630429 - Outbreak of type e botulism associated with an uneviscerated, salt-cured fish product--...
7600819 - Corneal subepithelial infiltrate recurrence sine adenovirus.
3291939 - Indomethacin retinopathy: case report and review.
23347849 - Some improvements are apparent in identifying adverse effects in systematic reviews fro...
23396309 - Swelling of the submandibular glands after administration of low-osmolarity contrast ag...
25039699 - Microscopic colitis: a review.
24679999 - What's new in objective assessment and treatment of facial hyperpigmentation?
16924199 - Ventral thoracic spinal cord herniation: frequently misdiagnosed entity.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European psychiatry : the journal of the Association of European Psychiatrists     Volume:  20     ISSN:  0924-9338     ISO Abbreviation:  Eur. Psychiatry     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-09-20     Completed Date:  2006-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111820     Medline TA:  Eur Psychiatry     Country:  France    
Other Details:
Languages:  eng     Pagination:  458-60     Citation Subset:  IM    
Centre Esquirol, Centre Hospitalier Universitaire de Caen, 14033 Caen cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents / therapeutic use
Antipsychotic Agents / therapeutic use
Anxiety / chemically induced,  drug therapy,  psychology
Depressive Disorder / chemically induced,  drug therapy,  psychology
Diagnosis, Differential
Hallucinogens / adverse effects*
Marijuana Smoking
Perceptual Disorders / chemically induced*,  diagnosis*,  drug therapy
Psilocybine / adverse effects*
Psychiatric Status Rating Scales
Risperidone / therapeutic use
Sertraline / therapeutic use
Social Behavior Disorders / chemically induced,  drug therapy,  psychology
Time Factors
Reg. No./Substance:
0/Antidepressive Agents; 0/Antipsychotic Agents; 0/Hallucinogens; 106266-06-2/Risperidone; 520-52-5/Psilocybine; 79617-96-2/Sertraline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Research on mental disorders and their care in immigrant populations: a review of publications from ...
Next Document:  Prevalence and incidence of Parkinson's disease in Europe.